# EDGAR Filing Document

**Accession Number:** 0001485003
**File Stem:** 0001485003-23-000077
**Filing Date:** 2023-2
**Character Count:** 15526
**Document Hash:** 7c446812779dae835ed18333f7ebd04e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001485003-23-000077.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001485003-23-000077

**CONFORMED SUBMISSION TYPE**: 425

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sesen Bio, Inc.
- **CENTRAL INDEX KEY:** 0001485003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 262025616
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36296
- **FILM NUMBER:** 23675488

**BUSINESS ADDRESS:**
- **STREET 1:** 245 FIRST STREET
- **STREET 2:** SUITE 1800
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-444-8550

**MAIL ADDRESS:**
- **STREET 1:** 245 FIRST STREET
- **STREET 2:** SUITE 1800
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eleven Biotherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20100223
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sesen Bio, Inc.
- **CENTRAL INDEX KEY:** 0001485003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 262025616
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425

**BUSINESS ADDRESS:**
- **STREET 1:** 245 FIRST STREET
- **STREET 2:** SUITE 1800
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-444-8550

**MAIL ADDRESS:**
- **STREET 1:** 245 FIRST STREET
- **STREET 2:** SUITE 1800
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eleven Biotherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20100223

![](form425-sesncarminfograp001.jpg)

Maximizing Value for Sesen Bio Stockholders + Proxy Advisory & Stockholder Support Cutting-Edge Immunotherapy Platform with Long-Term Upside Opportunity Substantial & Immediate Cash Value, Meaningfully Better Than the Alternative STEVEN KELLY President & CEO MICHAEL KLICHINSKY, PHD Co-Founder & Chief Scientific Officer BML INVESTMENT PARTNERS, L.P. (4.1% Ownership) With a substantial special cash dividend, enhanced CVR and exciting long-term potential of Carisma, we believe this represents the best path forward for Sesen Bio and its stockholders and we are pleased to support the pending merger. " " "INVESTOR GROUP1 (8.7% Ownership) We believe the amended merger terms represent the most value maximizing path for stockholders. CAR-M Leader Strong Leadership Team & Advisors Cutting edge research and bioengineering Validating partnership with Moderna Pioneering revolutionary cell therapy technology Evaluating first program in human clinical trials Strong patent position Early clinical data Multiple potential value inflection points expected over next 18 months TotalCVRPro Forma Company Special Cash Dividend $75M Special Cash Dividend 24.2% Stake in $352M3 Combined Company $30M CVR4 with Additional Upside Implied Total Value4 $0.14 Per Share $0.88 Per Share $0.40–$0.60 Per Share$0.38 Per Share $0.36 Per Share2 Dissolution and Liquidation Carisma Merger Additional Expense and Claims Management – Only ~60–90%5 of cash balance estimated to be available for initial distribution to stockholders, ~$0.40–$0.606 per share – Remaining amount would fund wind-down of operations and reserves for current, potential future and unknown liabilities Long Delay – Up to six months or more after an additional stockholder vote to approve dissolution and liquidation – Up to three years to fully settle after wind down Significant Uncertainty – Near-term special cash dividend without a concurrent transaction extremely unlikely outside the statutory dissolution process – Amount and timing of an initial distribution in a dissolution and liquidation process is uncertain The Sesen Bio Board of Directors unanimously urges all stockholders to vote "FOR" ALL agenda items TODAY! ISS and Glass Lewis, two leading independent proxy advisory firms, recommend stockholders vote "FOR" ALL proposals, including the pending merger with Carisma 7 DIRECTORS 8 KEY SCIENTIFIC ADVISORS with extensive cell therapy experience and strong track records in oncology and drug development with invaluable scientific knowledge and expertise to advance CAR-M and other therapies " Filed by Sesen Bio, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Sesen Bio, Inc. Commission File No.: 001-36296

------

![](form425-sesncarminfograp002.jpg)

Cautionary Note on Forward-Looking Statements Any statements in this communication about future expectations, plans and prospects for Sesen Bio, Inc. (Sesen Bio), CARISMA Therapeutics Inc. (Carisma) or the combined company, Sesen Bio's, Carisma's or the combined company's strategy or future operations, and other statements containing the words "anticipate," "believe," "contemplate," "expect," "intend," "may," "plan," "predict," "target," "potential," "possible," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. For example, statements concerning the proposed transaction, the concurrent financing, the contingent value rights and other matters, including without limitation: statements relating to the satisfaction of the conditions to and consummation of the proposed transaction, the expected timing of the consummation of the proposed transaction, the expected ownership percentages of the combined company, Sesen Bio's and Carisma's respective businesses, the strategy of the combined company, future operations, advancement of the combined company's product candidates and product pipeline, clinical development of the combined company's product candidates, including expectations regarding timing of initiation and results of clinical trials of the combined company, the ability of Sesen Bio to remain listed on the Nasdaq Stock Market, the completion of the concurrent financing, the receipt of any payments under the contingent value rights, and the amount and timing of distributions to be made to Sesen Bio stockholders, if any, in connection with any potential dissolution or liquidation scenario are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including without limitation: (i) the risk that the conditions to the closing of the proposed transaction are not satisfied, including the failure to obtain stockholder approval of matters related to the proposed transaction in a timely manner or at all; (ii) uncertainties as to the timing of the consummation of the proposed transaction and the ability of each of Sesen Bio and Carisma to consummate the proposed transaction, including completing the concurrent financing; (iii) risks related to Sesen Bio's ability to correctly estimate its expected net cash at closing and Sesen Bio's and Carisma's ability to correctly estimate and manage their respective operating expenses and expenses associated with the proposed transaction; (iv) risks related to Sesen Bio's continued listing on the Nasdaq Stock Market until closing of the proposed transaction; (v) the risk that as a result of adjustments to the exchange ratio, Sesen Bio stockholders or Carisma stockholders could own less of the combined company than is currently anticipated; (vi) the risk that the conditions to payment under the contingent value rights will not be met and that the contingent value rights may otherwise never deliver any value to Sesen Bio stockholders; (vii) risks associated with the possible failure to realize certain anticipated benefits of the proposed transaction, including with respect to future financial and operating results; (viii) uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources; (ix) the effect of uncertainties related to the actions of activist stockholders, which could make it more difficult to obtain the approval of Sesen Bio stockholders with respect to the transaction related proposals and result in Sesen Bio incurring significant fees and other expenses, including for third-party advisors; (x) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement, as amended; (xi) the effect of the announcement, pendency or completion of the merger on Sesen Bio's or Carisma's business relationships, operating results and business generally; (xii) costs related to the merger; (xiii) the outcome of any legal proceedings instituted against Sesen Bio, Carisma or any of their respective directors or officers related to the merger agreement or the transactions contemplated thereby; (xiv) the ability of Sesen Bio or Carisma to protect their respective intellectual property rights; (xv) competitive responses to the proposed transaction and changes in expected or existing competition; (xvi) the success and timing of regulatory submissions and pre-clinical and clinical trials; (xvii) regulatory requirements or developments; (xviii) changes to clinical trial designs and regulatory pathways; (xix) changes in capital resource requirements; (xx) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (xxi) legislative, regulatory, political and economic developments; and (xxii) other factors discussed in the "Risk Factors" section of Sesen Bio's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities Exchange Commission (SEC). In addition, the forward-looking statements included in this communication represent Sesen Bio's and Carisma's views as of the date hereof. Sesen Bio and Carisma anticipate that subsequent events and developments will cause the respective company's views to change. However, while Sesen Bio may elect to update these forward-looking statements at some point in the future, Sesen Bio specifically disclaims any obligation to do so, except as required under applicable law. These forward-looking statements should not be relied upon as representing Sesen Bio's views as of any date subsequent to the date hereof. Important Additional Information In connection with the proposed transaction between Carisma and Sesen Bio, Sesen Bio first mailed to Sesen Bio stockholders a definitive proxy statement/ prospectus on or about January 24, 2023 and a supplement to the proxy statement/prospectus on or about January 17, 2023. Sesen Bio may also file other relevant documents regarding the proposed transaction with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS, INCLUDING THE REGISTRATION STATEMENT, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS, THE SUPPLEMENT AND ALL OTHER RELEVANT DOCUMENTS THAT ARE OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE MATERIALS, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and security holders are able to obtain the definitive proxy statement/ prospectus and other documents that are filed or will be filed by Sesen Bio with the SEC free of charge from the SEC's website at www.sec.gov or from Sesen Bio at the SEC Filings section of www.sesenbio.com. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, a public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone or internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. Participants in the Solicitation Sesen Bio and Carisma and their respective directors, executive officers and other members of management may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Sesen Bio's directors and executive officers is available in Sesen Bio's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its definitive proxy statement dated April 28, 2022 for its 2022 Annual Meeting of Stockholders and its Current Report on Form 8-K filed with the SEC on August 31, 2022. Other information regarding the participants in the proxy solicitation and a description of their interests in the proposed transaction, by security holdings or otherwise, is included in the definitive proxy statement/prospectus and other relevant materials that are or will be filed with the SEC regarding the proposed transaction. Investors should read the definitive proxy statement/ prospectus carefully before making any voting or investment decisions. You may obtain free copies of these documents from Sesen Bio or the SEC's website as indicated above. Footnotes 1. Bradley L. Radoff and Michael Torok (together with their respective affiliates, the "Investor Group"). 2. Based on basic outstanding shares including unvested RSUs. 3. Reflects pro forma company value including estimated equity value of Carisma (~$196.0 million), implied value of Sesen Bio (~$85.0 million assuming $70.0 million cash available at closing), aggregate proceeds from Carisma pre-closing financing (~$30.6 million) and fully diluted value of the Moderna convertible note (~$40.1 million). 4. Amounts reflect potential payments in the future and have not been discounted. Does not include potential proceeds from Vicineum or the Company's other legacy assets. 5. Based on precedent liquidation processes and Company projections of potential liabilities and operating expenses. 6. Assumes stockholder approval of dissolution in 2Q 2023 and a cash balance of approximately $140 million at the estimated time of initial distribution. Call Toll-Free: 1-800-322-2885 (TOLL-FREE) Email: proxy@mackenziepartners.com For stockholders of record: For stockholders whose shares are held for your account by a broker, bank or other nominee: By Internet Have your proxy card in hand and log into the website printed on your proxy card. By Telephone Call the phone number printed on your proxy card. By Mail Mark, sign and date your proxy card and return it in the postage-paid envelope provided. Follow the instructions received from your broker, bank or other nominee.

------